Sanofi Stock

Equities

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris 11:37:17 2024-05-06 am EDT 5-day change 1st Jan Change
91.02 EUR -0.31% Intraday chart for Sanofi -0.89% +1.40%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2024 * 46.24B 49.79B Sales 2025 * 49.92B 53.76B Capitalization 114B 122B
Net income 2024 * 7.13B 7.68B Net income 2025 * 8.66B 9.32B EV / Sales 2024 * 2.6 x
Net Debt 2024 * 6.56B 7.07B Net Debt 2025 * 1.95B 2.1B EV / Sales 2025 * 2.32 x
P/E ratio 2024 *
16.1 x
P/E ratio 2025 *
13.2 x
Employees 86,088
Yield 2024 *
4.23%
Yield 2025 *
4.47%
Free-Float 87.12%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.31%
1 week-0.89%
Current month-2.21%
1 month+4.21%
3 months+4.34%
6 months+7.16%
Current year+1.40%
More quotes
1 week
90.81
Extreme 90.81
94.03
1 month
85.07
Extreme 85.07
94.03
Current year
84.93
Extreme 84.93
96.50
1 year
80.60
Extreme 80.6
104.32
3 years
76.45
Extreme 76.45
106.66
5 years
67.65
Extreme 67.65
106.66
10 years
62.50
Extreme 62.5
106.66
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 40 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 62 20-04-27
Director/Board Member 64 20-05-21
More insiders
Date Price Change Volume
24-05-06 91.02 -0.31% 605,355
24-05-03 91.3 -0.65% 891,417
24-05-02 91.9 -1.27% 1,753,124
24-04-30 93.08 +1.35% 2,031,482

Real-time Euronext Paris, May 06, 2024 at 11:37 am EDT

More quotes
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
91.02 EUR
Average target price
108.1 EUR
Spread / Average Target
+18.72%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW